{
  "compound": "Dronabinol, nabilone",
  "condition": "NAUSEA_CHEMOTHERAPY",
  "effect_size": "N/A (guideline)",
  "study_type": "CLINICAL_GUIDELINE",
  "source": "NORML:CINV_GUIDELINE_001",
  "participants": "Guideline based on systematic evidence review",
  "year": 2017,
  "notes": "ASCO Clinical Practice Guideline: Antiemetics Including Cannabinoids",
  "confidence": "medium",
  "abstract": "Grade 2A recommendation: Cannabinoids may be useful for BREAKTHROUGH CINV; Consider for refractory patients; Position as rescue therapy"
}